Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(Reuters) – India’s Zydus Lifesciences reported third-quarter profit above analysts’ expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market. The drugmaker’s ...

Zydus Lifesciences Ltd. reported US formulation sales that were ahead of expectations during the December quarter on Wednesday, February 5. Despite this, the stock has declined to the lows of the day.

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the 25th anniversary of its Vashi plant. The facility is crucial for ...

This commitment to science, health and innovation always inspired me. I am fortunate to have 27000 people at Zydus as a part of this journey working on putting India at the forefront of innovation ...

This commitment to science, health and innovation always inspired me,” Pankaj Patel said in a statement. “I am fortunate to have 27,000 people at Zydus as a part of this journey working on ...

“This commitment to science, health and innovation always inspired me. I am fortunate to have 27000 people at Zydus as a part of this journey working on putting India at the forefront of innovation ...